Details

Autor(en) / Beteiligte

• Gantenbein, Andreas R.
• Bonvin, Christophe
• Kamm, Christian P.
• Schankin, Christoph J.
• Zecca, Chiara
• Zieglgänsberger, Dominik
• Merki-Feld, Gabriele Susanne
• Pohl, Heiko
• Rudolph, Nicole
• Ryvlin, Philippe
• Agosti, Reto
• Schäfer, Elisabeth
• Meyer, Ina
• Kulartz-Schank, Monika
• Arzt, Michael E.

Titel

Implications of therapy interruption on monthly migraine days and modified migraine disability assessment in patients treated with erenumab for chronic and episodic migraine: SQUARE study interim results

Ist Teil von

• Journal of neurology, 2024-08, Vol.271 (8), p.5402-5410

Ort / Verlag

Berlin/Heidelberg: Springer Berlin Heidelberg

Erscheinungsjahr

2024

Quelle

MEDLINE

Beschreibungen/Notizen

• Background There are limited real-world data in Switzerland examining the impact of erenumab, a fully human IgG2 monoclonal antibody targeting the calcitonin gene-related peptide (CGRP) receptor, on migraine-related quality of life. Objective This 18-month interim analysis of 172 patients with episodic or chronic migraine from the SQUARE study provides first prospective insights on the impact of mandatory erenumab treatment interruption, following Swiss-reimbursement requirements, in a real-world clinical setting in Switzerland. Findings Recruited patients receiving 70 or 140 mg erenumab underwent treatment interruption on average 11.2 months after therapy onset with a mean duration of 4 months. There were sustained improvements in mean monthly migraine days (MMD) and migraine disability (mMIDAS) during initial treatment with erenumab. Treatment interruption was associated with a temporary worsening of condition. Symptoms ameliorated upon therapy reuptake reaching improvements similar to pre-break within 3 months. Conclusions Treatment interruption was associated with a temporary worsening of condition, which improved again after therapy restart.